Publications by Dr Nicola Cresti - ePrints

Browsing publications by Dr Nicola Cresti.

Newcastle Authors	Title	Year
Dr David Austin Rebecca Maier Dr Nicola Cresti Dr Mark Verrill Dr Wendy Osborne et al.	Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma: The PROACT Clinical Trial	2024
Dr Jingky Lozano-Kuehne Dr Nicola Cresti Professor Ruth Plummer	Results of the Phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer	2022
Dr Nicola Cresti	A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer	2020
Ali Kucukmetin Dr Nicola Cresti Dr Rachel O'Donnell	BRAF Wild-type, PTEN Mutant Malignant Uveal Melanoma Arising Within a Mature Ovarian Teratoma: A Case Report and Review of the Literature	2020
Dr Nicola Cresti Dr Yvette Drew	First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor	2020
Dr Nicola Cresti Professor Ruth Plummer	A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine	2019
Dr David Jamieson Dr Jo Lee Dr Nicola Cresti Melanie Griffin Julieann Sludden et al.	Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil	2014
Professor Ruth Plummer Dr Nicola Cresti Dr Yvette Drew Dr Peter Stephens Dr Jared Thornton et al.	Phase 1 study of the PARP inhibitor E7449 as a single agent in patients with advanced solid tumors or B-cell lymphoma	2014
Dr Nicola Cresti Professor Ruth Plummer	A phase 1 study of oral rucaparib in combination with carboplatin	2013
Dr Nicola Cresti Dr Yvette Drew Professor Ruth Plummer	A phase I study of oral rucaparib in combination with carboplatin	2013
Dr Nicola Cresti Dr Chris Plummer	Cardiac troponin release following standard dose anthracycline-based adjuvant chemotherapy	2013
Dr Nicola Cresti Professor Ruth Plummer	Pharmacokinetics of eribulin mesilate in combination with capecitabine in patients with advanced/metastatic cancer: Results from a phase IB dose-escalation study	2012
Dr David Jamieson Dr Nicola Cresti Julieann Sludden Melanie Griffin Nahed Hawsawi et al.	Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy	2011
Dr Nicola Cresti Dr David Jamieson	The pharmacology of trastuzumab and its use in breast cancer	2010
Dr David Jamieson Dr Nicola Cresti Dr Mark Verrill Professor Alan Boddy	Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma	2009